Stroke Prevention in Atrial Fibrillation
The Medical Center – University Of Freiburg conducts research in cardiovascular diseases, focusing on atrial fibrillation and the risk of stroke. Current studies compare the novel anticoagulant asundexian with the established therapy apixaban to determine efficacy and safety.
- Comparison of new anticoagulant with standard therapy
- Evaluation of major bleeding outcomes
- Overall benefit‑risk assessment for stroke prevention
Twelve investigators are involved in these trials, aiming to improve treatment options for patients at high risk of stroke.
Self‑Administered Treatment for Acute Myocardial Infarction
In the field of cardiovascular disease, the site evaluates the rapid‑action drug selatogrel when patients self‑administer it at the onset of symptoms suggestive of an acute myocardial infarction. The goal is to demonstrate that early, patient‑initiated therapy can reduce recurrent heart attacks.
- Patient‑initiated drug delivery
- Early recognition of heart attack symptoms
- Impact on rates of recurrent myocardial infarction
The trial involves a multidisciplinary team of cardiologists and pharmacologists working to enhance emergency care for heart attack patients.
Lipoprotein(a) Targeting in Atherosclerotic Cardiovascular Disease
Research at the center also addresses atherosclerotic cardiovascular disease with elevated lipoprotein(a) levels. The investigational agent olpasiran is being tested for its ability to lower Lp(a) and reduce major cardiovascular events such as coronary heart disease death and urgent revascularization.
- Lp(a) lowering strategy
- Effect on coronary heart disease mortality
- Potential to decrease need for urgent revascularization
This study seeks to provide new therapeutic options for patients with high cardiovascular risk linked to Lp(a) elevation.
